Across TCGA pan-cancer cohorts, SULT1A2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SULT1A2 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SULT1A2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SULT1A2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and LSCC are the cancer types where SULT1A2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	II,III,IV	1.000	0.682	.015	18	view →
LUAD	DFS	Median	All	1.000	0.891	.014	9	view →
LSCC	OS	Quartile	All	0.707	0.944	.043	3	view →
PDAC	OS	Median	III,IV	0.621	1.000	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: SULT1A2 tumor-vs-normal RNA expression · all SULT1A2 data types